TLDR Taking high doses of Cyproterone acetate significantly increases the risk of meningioma in females.
This nationwide cohort study investigated the association between cyproterone acetate (CPA) use and the risk of meningioma in Denmark. The study included individuals born between 1930 and 2000, followed from age 15 or later until 2017. The findings indicated that high cumulative doses of CPA significantly increased the risk of meningioma, with a 6-20 fold higher risk compared to low doses. This led to the European Medicines Agency recommending a restriction of CPA to less than 10 mg per day. The study underscores the importance of monitoring CPA dosage to mitigate the risk of meningioma.
59 citations,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
January 2024 in “Pharmaceutical medicine” Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.
31 citations,
September 2020 in “Clinical endocrinology” Some antiandrogens may lower testosterone better than others, but it's unclear which is best for feminization in transgender women; more research is needed.
59 citations,
February 2021 in “BMJ” High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
88 citations,
May 2011 in “British Journal of Clinical Pharmacology” High doses of cyproterone acetate are linked to an increased risk of developing meningioma.
4 citations,
April 2016 in “Journal of Dermatology Research and Therapy” Anti-androgens are safe and effective for treating moderate to severe adult female acne.